Novocure is a medical devices business based in the US. Novocure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.49 – a decrease of 12.57% over the previous week. Novocure employs 1,488 staff and has a trailing 12-month revenue of around $605.2 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $16.49 |
|---|---|
| 52-week range | $11.70 - $34.13 |
| 50-day moving average | $20.87 |
| 200-day moving average | $20.47 |
| Wall St. target price | $34.71 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.56 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.49 from 2025-04-04
| 1 week (2025-03-28) | -12.57% |
|---|---|
| 1 month (2025-03-06) | -14.38% |
| 3 months (2025-01-06) | -44.40% |
| 6 months (2024-10-04) | 12.02% |
| 1 year (2024-04-05) | 20.01% |
|---|---|
| 2 years (2023-04-06) | -73.83% |
| 3 years (2022-04-06) | 85.3 |
| 5 years (2020-04-06) | 69.1 |
| Revenue TTM | $605.2 million |
|---|---|
| Gross profit TTM | $469 million |
| Return on assets TTM | -8.77% |
| Return on equity TTM | -46.67% |
| Profit margin | -27.86% |
| Book value | $3.32 |
| Market Capitalization | $1.8 billion |
TTM: trailing 12 months
We're not expecting Novocure to pay a dividend over the next 12 months.
Over the last 12 months, Novocure's shares have ranged in value from as little as $11.7 up to $34.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novocure's is 0.65. This would suggest that Novocure's shares are less volatile than average (for this exchange).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. .
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.